Zenas BioPharma (ZBIO) Shares Outstanding (Diluted Average) (2023 - 2026)
Zenas BioPharma (ZBIO) recorded quarterly Shares Outstanding (Diluted Average) of $55.6 million in Q1 2026, up 24.36% quarter-over-quarter from $44.7 million in Q4 2025, and up 33.07% on a YoY basis from $41.8 million in Q1 2025.
Zenas BioPharma (ZBIO) Shares Outstanding (Diluted Average) (2023 - 2026) Analysis & Trends
Zenas BioPharma's Shares Outstanding (Diluted Average) history runs 4 years deep, the most recent figure standing at $55.6 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 33.07% year-over-year to $55.6 million; the TTM figure through Mar 2026 stood at $55.6 million (up 33.07% YoY), while the FY2025 annual figure was $44.7 million, up 238.89% from the prior year.
- Shares Outstanding (Diluted Average) was $55.6 million for Q1 2026 at Zenas BioPharma, up from $44.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $55.6 million in Q1 2026 to a low of $1.5 million in Q4 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $24.7 million across 4 years, with a median of $27.5 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Diluted Average) jumped 2589.73% in 2025, then surged 33.07% in 2026.
- A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $1.5 million in 2023, then surged by 762.01% to $13.2 million in 2024, then jumped by 238.89% to $44.7 million in 2025, then climbed by 24.36% to $55.6 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $55.6 million (Q1 2026), $44.7 million (Q4 2025), and $41.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Zenas BioPharma | 1.10 Bn | 379.43 Mn | - | 55.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.62 Mn |
| Dec 31, 2025 | 44.73 Mn |
| Sep 30, 2025 | 41.94 Mn |
| Jun 30, 2025 | 41.87 Mn |
| Mar 31, 2025 | 41.80 Mn |
| Dec 31, 2024 | 13.20 Mn |
| Sep 30, 2024 | 3.62 Mn |
| Jun 30, 2024 | 1.57 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 1.53 Mn |